Hepatic function is a strong predictive factor of efficacy and safety of antiviral therapy in portal hypertensive hepatitis C virus-related liver cirrhosis

2007 ◽  
Vol 39 (3) ◽  
pp. A19
Author(s):  
B.E. Annicchiarico ◽  
M. Siciliano ◽  
P. Parente ◽  
A. Gasbarrini ◽  
G. Bombardieri
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Predictive Factor ◽  
Hepatic Function ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Kanzo ◽  
2020 ◽  
Vol 61 (5) ◽  
pp. 276-278
Author(s):  
Yoshinari Takaoka ◽  
Kouichi Miura ◽  
Naoki Morimoto ◽  
Satoru Kakizaki ◽  
Tadashi Ikegami ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Efficacy And Safety ◽  
Hepatitis C Virus Infection ◽  
Decompensated Liver Cirrhosis

scholarly journals HCV GENOTYPES AND ITS ASSOCIATION WITH RESPONSE TO TREATMENT

2020 ◽  
Vol 11 (2) ◽  
pp. 27-33
Author(s):  
Aftab Ahmad Khan ◽  
Naghmi Asif ◽  
Rizwan Uppal ◽  
Gul E Rehan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Sustained Viral Response ◽  
Viral Response ◽  
Hepatic Diseases ◽  
Diagnostic Center ◽  
Type 3

BACKGROUND & OBJECTIVE: primary Hepatitis C is a serious public health problem and is the cause of liver cirrhosis, hepatocellular carcinoma (HCC), and numerous end-stage liver disease manifestations. The management of hepatitis C is to preclude liver cirrhosis, lessen the risk of hepatocellular carcinoma or hepatoma, and curing the extra hepatic diseases. Initially, interferon was the cornerstone for treating hepatitis C, but due to its cumbersome complications, route of administration, and limited treatment access, many patients showed noncompliance. New therapies for chronic hepatitis C have been introduced based on direct antiviral effects. Several genotypes of hepatitis C have been discovered and they are responsive to different antiviral therapies. Our objective was to assess the genotypic distribution of HCV in our local setup and their pattern of response to different combination of anti-viral therapies by assessing the sustained viral response (SVR) after 12 weeks post-treatment. To determine the most prevalent genotype of hepatics C virus in our population and pattern of the response of multiple genotypes to different antiviral regimens. METHODOLOGY: It is a cross-sectional study conducted for duration of six months and recruited those patients whose polymerase chain reaction (PCR) was found positive for hepatitis C virus at Islamabad Diagnostic Center. We analyzed 100 patients, both children and adults. Patients were assessed for different genotypes and then different combinations of antiviral treatments were administered. Their clinical data, hematological parameters and viral load before and after treatment were also analyzed. RESULTS: In a total of 100 positive hepatitis C virus-infected patients, 55% were females and 45% males. The frequencies of genotypes observed were 91 %, 06%, and 03% of genotype 3, 1a, and 1b respectively. 51 out of 91 patients with type 3 genotype, who were on antiviral therapy of sofosbuvir and ribavirin, all of them achieved SVR. 30 out of 91 patients with type 3 genotype were treated with sofosbuvir alone, the percentage of failure to achieve SVR in them was 6.7%. Treatment failure percentage of 10% was observed when a combination of Interferon (INF) alpha and ribavirin was used in type 3 genotype. Remaining six patients with type 1a and three patients of type 1b genotype achieved SVR with different regimens used. CONCLUSION: Although the increased load of HCV in our setup is an alarming situation the prevalence of type 3 genotype is a blessing in disguise. The success of sustained viral response after various combinations of direct antiviral therapy and interferon-free treatment is hope for the ultimate cure of the disease and avoidance of debilitating side effects related to interferon.

scholarly journals Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation

2017 ◽  
Vol 11 (3) ◽  
pp. 429-433 ◽  
Author(s):  
Suresh Reddy ◽  
Raj Kumar Sharma ◽  
Sonia Mehrotra ◽  
Narayan Prasad ◽  
Amit Gupta ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Antiviral Therapy ◽  
Efficacy And Safety ◽  
Hepatitis C Virus Infection
Sign in / Sign up

Export Citation Format

Share Document